Bernstein Liebhard LLP Announces Investigation Into the Proposed Sale of NCI, Inc.
August 8, 2017
Bernstein Liebhard LLP is investigating whether the Board of Directors of NCI, Inc. (“NCI” or the “Company”) (NASDAQ: NCIT) breached its fiduciary duty to its shareholders in agreeing to sell NCI to H.I.G. Capital, LLC (“H.I.G.”).
On July 3, 2017, NCI and H.I.G. announced the signing of a definitive merger agreement, pursuant to which H.I.G. would acquire NCI in merger, via a tender offer, worth $283 million.
Under the terms of the agreement, NCI shareholders are expected to receive $20.00 in cash for each share of common stock they own. Bernstein Liebhard’s investigation is focused on whether the Company’s Board of Directors failed to satisfy their duties to shareholders, including whether the Board adequately pursued alternatives to the acquisition and whether the Board obtained the best price possible for the Company’s shares of common stock.
Bernstein Liebhard LLP has pursued hundreds of securities, consumer and shareholder rights cases and recovered over $3.5 billion for its clients. The Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times.